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Abstract
 
The mechanisms by which CD8 effector populations interact with epithelial layers is a poorly
defined aspect of adaptive immunity. Recognition that CD8 effectors have the capacity to ex-
press CD103, an integrin directed to the epithelial cell-specific ligand E-cadherin, potentially
provides insight into such interactions. To assess the role of CD103 in promoting CD8-medi-
ated destruction of epithelial layers, we herein examined the capacity of mice with targeted
disruption of CD103 to reject pancreatic islet allografts. Wild-type hosts uniformly rejected is-
 
let allografts, concomitant with the appearance of CD8
 
 
 
CD103
 
 
 
 effectors at the graft site. In
 
contrast, the majority of islet allografts transplanted into CD103
 
 
 
/
 
 
 
 hosts survived indefi-
nitely. Transfer of wild-type CD8 cells into CD103
 
 
 
/
 
 
 
 hosts elicited prompt rejection of
long-surviving islet allografts, whereas CD103
 
 
 
/
 
 
 
 CD8 cells were completely ineffectual,
demonstrating that the defect resides at the level of the CD8 cell. CD8 cells in CD103
 
 
 
/
 
 
 
hosts exhibited normal effector responses to donor alloantigens in vitro and trafficked nor-
mally to the graft site, but strikingly failed to infiltrate the islet allograft itself. These data estab-
lish a causal relationship between CD8
 
 
 
CD103
 
 
 
 effectors and destruction of graft epithelial
elements and suggest that CD103 critically functions to promote intragraft migration of CD8
effectors into epithelial compartments.
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Introduction
 
CD8 effector populations play important roles in host de-
fense against intracellular parasites and tumors by direct
destruction of cells expressing foreign MHC/peptide com-
plexes, and it is widely accepted that donor-reactive CD8
effector populations play an analogous role in rejection of
transplanted tissues (1, 2). After activation by MHC/pep-
tide in the context of appropriate APC, naive, or memory
 
CD8
 
  
 
 
 
TCR-
 
  
 
 
 
 cells (CD8 cells) differentiate into
CD8 effector cells which efficiently eliminate cells ex-
pressing the target MHC class I/peptide alloantigen.
Ubiquitous expression of class I molecules combined with
loading of nascent class I molecules with peptides derived
from endogenous proteins, assures that all donor cell types
are susceptible to surveillance by CD8 effector popula-
tions. CD8 effectors possess a diverse and redundant arma-
mentarium for destruction of target cells including induc-
tion of apoptosis by cytotoxic granule release or Fas–FasL
pathways (3), and production of cytokines (4, 5) and che-
mokines (6) that regulate the effector activity of other leu-
kocyte populations (7).
The mechanisms by which CD8 effectors interact with
epithelial layers represents an important gap in our under-
standing of transplant immunity. The functional elements
of most organ systems (i.e., renal tubules, pancreatic islets,
hepatocytes, alveoli, etc.) are specialized epithelial layers,
and specific attack of such structures by alloreactive CD8
effector populations constitutes a major component of or-
gan allograft rejection (1, 2). Recent studies have provided
detailed insight into the cellular and molecular interactions
that promote trafficking of CD8 cells from the initial site of
activation within peripheral lymphoid compartments to the
graft site (8). However, little is known of the critical down-
 
Address correspondence to G.A. Hadley, University of Maryland Medical
School, Rm. 400 MSTF, 10 South Pine St., Baltimore, MD 21201. Phone:
410-706-0311; Fax: 410-706-0225; E-mail: ghadley@smail.umaryland.edu 
878
 
CD103-dependence of Pancreatic Islet Allograft Rejection
 
stream events by which CD8 effectors gain access to and
subsequently destroy graft epithelial compartments.
Previously, we have reported that alloreactive CD8 ef-
fector populations in both the mouse (9) and human (10)
systems have the capacity to express the integrin het-
erodimer 
 
 
 
E
 
(CD103)/
 
 
 
7
 
 (herein referred to as CD103).
These observations potentially provide insight into CD8
effector–epithelial interactions because the principal ligand
of CD103 is E-cadherin (11, 12), a tissue-restricted mole-
cule selectively expressed by cells comprising epithelial lay-
ers (13). CD103 is poorly expressed by conventional CD8
effector populations (i.e., in vitro generated CTL popula-
tions; references 9 and 14), but is readily induced by expo-
sure of such cells to bioactive TGF-
 
 
 
 (9). The relevance of
these data to transplant immunity is supported by the ob-
servation that CD103
 
 
 
CD8
 
 
 
 effectors accumulate in the
kidney but not the spleen in a mouse model of GVHD (9),
and are present at the site of clinical renal allograft rejection
(10). CD8
 
 
 
CD103
 
 
 
 effectors that infiltrate rejecting renal
allografts preferentially accumulate within graft epithelial
compartments (10, 15), consistent with a key role for this
effector subset in the rejection process.
CD103 was initially identified by its high level expres-
sion on the heterogeneous and poorly-defined T cell popu-
lations that reside within and adjacent to the mucosal epi-
thelia of normal mice (16) and humans (17); intraepithelial
and lamina propria lymphocytes, respectively (IEL and
LPL)
 
*
 
. In contrast, CD103 is poorly expressed by T cells in
lymphoid compartments such as the blood, spleen, and
lymph nodes (16, 17). Consequently, previous studies of
CD103 have focused almost exclusively on its potential
role in retaining T cells at mucosal sites. Consistent with
this possibility, mice with targeted disruption of CD103
exhibit a mild deficiency of T cells in the IEL and LPL
compartments (18). It is important to note, however, that
CD103-deficient mice are otherwise phenotypically nor-
mal, and that the deficiency in mucosal T cells is highly
dependent on genetic background and environmental in-
fluences (18). Moreover, Lefrancois et al. (19) recently
reported that CD103 expression is not required for long-
term retention of antigen-specific CD8 cells in the intesti-
nal epithelium. Thus, the functional significance of CD103
expression by T cells remains unclear.
The goal of this study was to determine if CD103 ex-
pression is required for destruction of graft epithelial ele-
ments by alloreactive CD8 cells. To test this hypothesis, we
examined the capacity of mice with targeted disruption of
the CD103-encoding gene (
 
Itgae
 
) (18) to reject pancreatic
islet allografts. Pancreatic islets express both MHC class I
and the CD103 ligand, E-cadherin (20), and thus should be
susceptible to destruction by alloreactive CD103
 
 
 
CD8
 
 
 
effectors. We report that CD103
 
 
 
/
 
 
 
 hosts are strikingly de-
ficient in the capacity to reject islet allografts, and provide
evidence that the relevant defect resides at the level of in-
 
tragraft migration of CD8 effector populations. These data
are consistent with a critical role for CD103 in promoting
entry and/or retention of antigen-specific CD8 effector
populations in epithelial compartments.
 
Materials and Methods
 
Mice.
 
Female A/J and BALB/cJ mice (age 6 wk) were pur-
chased from The Jackson Laboratory and maintained under patho-
gen-free housing conditions at the University of Maryland, Balti-
more, MD. Breeding stocks of mice with targeted disruption of
the CD103 (
 
Itgae
 
) gene (18) were bred and maintained (by C.M.
Parker, Brigham and Women’s Hospital, Boston, MA) under
pathogen-free conditions at the University of Maryland animal fa-
cilities. Two different strains of CD103
 
 
 
/
 
 
 
 mice were used in this
study. Initially, CD103
 
 
 
/
 
 
 
 mice backcrossed 10 generations to the
BALB/c strain were used; wild-type BALB/cJ mice purchased
from The Jackson Laboratory served as CD103
 
 
 
/
 
 
 
 controls. Sub-
sequently, a CD103
 
 
 
/
 
 
 
 strain rigorously selected to differ from
BALB/c at only the 
 
Itgae
 
 locus were used for experiments; this
congenic strain, designated C;129S2-Itgae
 
tm1Cmp
 
, has been depos-
ited at The Jackson Laboratory. In this case, wild-type BALB/c
mice bred in the University of Maryland animal facility in parallel
with C; 129S2-Itgae
 
tm1Cmp
 
 mice served as CD103
 
 
 
/
 
 
 
 controls.
The two CD103
 
 
 
/
 
 
 
 strains gave identical results compared with
their respective wild-type controls with regard to all parameters
examined herein. Breeding stocks for BALB/c-Thy1.1 congenic
mice were provided by H. Levitsky (Johns Hopkins Medical
School, Baltimore, MD). BALB/c hosts expressing both Thy1.1
and Thy1.2 were obtained by interbreeding BALB/c-Thy1.1
mice with BALB/cJ mice (Thy1.2
 
 
 
) to produce F
 
1
 
 hybrid mice.
 
Antibodies. 
 
mAbs to mouse CD8 (3.155), CD103 (M290)
(21), CD4 (GK1.5), and MHC class II (212.A1), were purified
from hybridoma culture supernatants and conjugated to FITC by
Bioexpress Cell Culture Services (West Lebanon, NH); mAbs to
mouse CD4 (RL172.4), HSA, (J11D.B1), and H-2-IA
 
d
 
 (MKD6)
used for complement depletion were used as hybridoma culture
supernatants. FITC- and CyChrome-conjugated mAbs to mouse
CD8a, and PE-conjugated mAbs to mouse CD8b, CD11a,
CD62L, CD44, TCR-
 
  
 
, CD8.2, Thy1.1, Thy1.2, and the re-
spective species- and isotype-matched negative control mAbs
were purchased from BD PharMingen.
 
Pancreatic Islet and Skin Transplantation.
 
Islets for transplanta-
tion were prepared as described by Gotoh et al. (22). In brief,
HBSS (GIBCO BRL) containing 2 mg/ml collagenase (Sigma-
Aldrich) was injected into the common bile duct of donor mice.
The distended pancreas was removed and incubated at 37
 
 
 
C for
16 min, and the released islets were enriched by centrifugation on
a discontinuous Ficoll (Sigma-Aldrich) gradient. Tissue fragments
collected at the 21.5% interface were washed and resuspended in
HBSS. Individual islets, free of attached acinar, vascular, and duc-
tal tissue were selected under a dissecting microscope, yielding
highly purified islets for transplantation. Recipients were ren-
dered diabetic by injection of 220 mg/kg streptozotocin intra-
peritoneally 3–6 d before transplantation. An incision was made
to expose the recipient’s left kidney, and 500 fresh islets were in-
jected into the renal subcapsular space. After recovery from anes-
thesia, recipients were maintained under pathogen-free condi-
tions, and blood glucose levels were monitored on a daily basis.
Rejection was defined as BG 
 
 
 
300 mg/dL.
Skin transplantation was performed as described by Stein-
muller (23). After 6 d, the bandages were removed and the grafts
 
*
 
Abbreviations used in this paper:
 
 GIL, graft infiltrating lymphocyte; ICAM,
intracellular adhesion molecule; IEL, intraepithelial lymphocyte; LPL,
lamina propria lymphocyte; SC, spleen cell. 
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were assessed daily; rejection was defined as the day on which
100% graft scabbing was recorded.
 
FACS
 
®
 
 Analyses.
 
Graft infiltrating lymphocytes (GILs) were
isolated by mincing the graft and incubation for 30 min in media
containing collagenase (Worthington Biochemical Corp.), soy-
bean trypsin inhibitor (Sigma-Aldrich), and DNase (Boehringer
Mannheim). Lymphocytes were isolated by centrifugation on
Lympholyte-M (Cedarlane Laboratories Limited). For two-color
FACS
 
®
 
 analyses, cells were stained with PE-conjugated mAb to
CD8b in combination with FITC-conjugated mAbs to markers
of interest. For three-color analyses, cells were stained with anti-
CD8a-CyChrome in combination with FITC- and PE-conju-
gated mAbs. Species and isotype-matched mAbs of irrelevant
specificity were used as controls for nonspecific fluorescence. Af-
ter staining, cells were fixed with 0.5% paraformaldehyde, and
3–6 
 
 
 
 10
 
4
 
 cells were analyzed using a FACScan™ (Becton Dick-
inson). Intracellular cytokine staining for FACS
 
®
 
 was performed
using an intracellular cytokine staining kit (no. 2040KK) pur-
chased from BD PharMingen. In brief, GILs isolated as described
above were cultured in media containing PMA, ionomycin, and
monensin for 4 h, then permeabilized and stained with anti-
CD8a-FITC followed by PE-coupled mAbs to IFN-
 
 
 
 or TNF-
 
 
 
.
Lymphocyte populations were gated by forward scatter/side scat-
ter analysis to exclude monocytes and debris. WinMDI 2.8 soft-
ware (downloaded from: http://facs.scripps.edu/software.html)
developed by Joseph Trotter (Scripps Institute, La Jolla, CA) was
used for analysis and graphic display of flow cytometry data. The
percentage of positive cells for a given marker was based on cutoff
points chosen to exclude 
 
 
 
99% of the negative control popula-
tion.
 
In Vitro Generation of CD8 Effectors.
 
CD8 effectors for 
 
51
 
[Cr]
release assays and cytokine production assays were generated by
coculturing 10 
 
 
 
 10
 
6
 
 spleen cells (SCs) from CD103
 
 
 
/
 
 
 
 or
CD103
 
 
 
/
 
 
 
 donors with 10 
 
 
 
 10
 
6
 
 irradiated (3,000 rads) A/J SCs
in upright 25 cm
 
2
 
 culture flasks in 20 ml RPMI 1640 supple-
mented with sodium pyruvate, nonessential amino acids, 10 mM
Hepes, 50 uM 2-ME, and 10% FCS (RPMI
 
 
 
). Red cells were
removed from SC stimulators by treatment with RBC lysing
buffer (Sigma-Aldrich). After 5 d, cultures were harvested and
treated with a cocktail of mAbs to CD4 (RL172.4), HSA,
(J11D.B1), and H-2-IA
 
d
 
 (MKD6) followed by incubation in 1:10
Low-Tox M rabbit complement (Accurate) and centrifugation on
Lympholyte-M. The resulting effector population contained
 
 
 
95% CD8
 
 
 
TCR-
 
  
 
 
 
 cells as determined by FACS
 
®
 
.
 
T Cell Functional Assays.
 
51
 
[Cr] release assays were performed
as described previously (9). For targets, Con A blasts were prepared
by culturing 25 
 
 
 
 10
 
6
 
 red cell–depleted SCs from BALB/cJ or A/J
donors for 3 d in 10 ml of RPMI
 
 
 
 containing 5 ug/ml Con A
(Sigma-Aldrich). For cytokine production assays, 10
 
6
 
 CD8 effec-
tors were restimulated with 10
 
6
 
 RBC-depleted A/J SCs (3,000
rads) in 2 ml of RPMI
 
 
 
. Supernatants from replicate cultures (
 
n 
 
 
 
3) were harvested at various intervals and subjected to cytokine-
specific ELISA by the University of Maryland Cytokine Core Lab-
oratory to measure concentrations of IFN-
 
 
 
 and TNF-
 
 
 
.
 
Adoptive Transfer Models.
 
For adoptive transfer of CD8 cells
into CD103
 
 
 
/
 
 
 
 hosts with long-surviving A/J allografts, wild-
type, or CD103-deficient mice (6-wk-old females) to be used as
lymphocyte donors were injected intraperitoneally with 10 
 
 
 
 10
 
6
 
A/J SCs. On day 4, spleens and abdominal lymph nodes were
harvested and centrifuged on Lympholyte-M (Cedarlane Labora-
tories Limited) to remove RBCs. The resulting cell suspension
was enriched for CD8
 
 
 
 T cells by immunomagnetic depletion
with mAbs to mouse class MHC class II (212.A1) and CD4
(GK1.5) followed by anti–rat IgG-, anti–mouse IgG-, and anti–
mouse IgM-coupled magnetic beads (Polysciences). The nega-
tively selected cell population comprised 
 
 
 
60% CD8
 
 
 
 
 
T cells
with 
 
 
 
0.1% CD4
 
 
 
 T cells. To assure that equivalent numbers of
CD8 cells were transferred in different experiments, FACS
 
® 
 
anal-
yses using anti-CD8 and TCR-
 
   
 
was performed on each prep-
aration to assess the degree of enrichment for CD8
 
 
 
 T cells. 50 
 
 
 
10
 
6
 
 CD8
 
 
 
 T cells were then injected into CD103
 
 
 
/
 
 
 
 recipients
with long-surviving A/J allografts by the tail vein, and blood glu-
cose levels were monitored on a daily basis. In some experiments,
CD8 cells were removed from the above “CD8” preparations by
incubation with mAb to mouse CD8 (3.155) followed by com-
plement. Such preparations contained 
 
 
 
98% non-T cells (pre-
dominantly B cells) with 
 
 
 
0.01% CD8
 
 
 
 T cells.
For adoptive transfer experiments to assess the relative effi-
ciency with which CD103-deficient CD8 effectors traffic to the
graft site, purified CD8 cells from naive CD103
 
 
 
/
 
  (Thy1.1 /
1.2 ) and CD103 /  (Thy1.1 /1.2 ) donors were prepared as
described above. 5   106 cells of each type were then injected
intravenously into streptozotocin-treated (diabetic) BALB/c-
Thy1.1    BALB/cJ F1 hosts (Thy1.1 /Thy1.2 ) which were
transplanted with 500 A/J islets the following day. Blood glucose
levels were monitored on a daily basis. At the time of early rejec-
tion (BG   200 mg/dL), graft infiltrating lymphocytes were
isolated and stained for three-color FACS® analyses with anti-
Thy1.1-PE and anti-Thy1.2-FITC in combination with anti-
CD8-CyChrome to discriminate host CD8 cells from each of the
transferred CD8 populations.
Results
CD8 CD103  Effectors Are Present at the Site of Islet Al-
lograft Rejection in Wild-Type Hosts. As shown in Fig. 1 A,
A/J islet allografts (H-2a) transplanted into diabetic wild-
type recipients (BALB/c, H-2d) were promptly rejected (n  
13, MST   13.8 d). Recipient mice were hyperglycemic
before transplant and transiently returned to a normoglyce-
mic state 2–6 d after receiving A/J islet allografts (Fig. 1 A).
In contrast, BALB/c recipients of islet isografts remained
normoglycemic throughout the observation period ( 300 d),
confirming that the rapid return to a hyperglycemic state
noted in allograft recipients reflects immunologic rejection
(Fig. 1 A).
FACS® analyses of GILs isolated from islet allografts at
the time of rejection in wild-type hosts revealed a predom-
inant population of CD8 cells (Fig. 2 A). Fig. 2 A further
demonstrates that CD103 was expressed by a major subset
of the CD8  GIL population at the time of rejection. Note
that CD103 expression by GILs was restricted almost ex-
clusively to CD8 TCR-    cells. In four replicate experi-
ments, 18.1   3.0% of CD8  GILs expressed CD103 at
levels significantly above background staining. Fig. 2 B
shows that CD8  GILs were CD62L CD44hiCD11ahi 
TCR-    consistent with an effector phenotype. These
data indicated that CD8 CD103  effectors are present in
the graft at the time of rejection, consistent with a role for
these cells in the rejection process.
Mice With Targeted Disruption of CD103 Exhibit a Specific
Defect in the Capacity for Islet Allograft Rejection. Mice with
targeted disruption of the CD103-encoding gene (Itae)880 CD103-dependence of Pancreatic Islet Allograft Rejection
were used as recipients of islet allografts to directly assess
the role of CD103 in islet allograft destruction. The
CD103 /  mice used in this study were backcrossed 10
generations to the BALB/c strain; such mice completely
fail to express the CD103 heterodimer ( E 7) but are phe-
notypically indistinguishable from wild-type cohorts except
for slightly reduced numbers of T cells diffusely distributed
in the intestinal epithelium (18).
As shown in Fig. 1 B, CD103 /  hosts were highly defi-
cient in their capacity to reject A/J islet allografts with the
majority of allografts (11/17) surviving indefinitely. Impor-
tantly, removal of long-surviving allografts by unilateral ne-
phrectomy (n   3) resulted in a prompt return to hypergly-
cemia (Fig. 1 C), thereby confirming that the prolonged
normoglycemic state was a reflection of stable graft func-
tion rather than the persistence of host islet function i.e.,
due to inadequate streptozotocin treatment.
The Defect in CD103 /  Hosts Resides at the Level of the
CD8 Cell. Adoptive transfer experiments were used to
determine if the defect in CD103 /  mice resides at the
level of the CD8 cell. This is a critical point because
CD103 is also expressed by non-CD8 cells including den-
dritic cells (24), macrophages (25), and mast cells (26),
which potentially could contribute to allograft rejection. In
these experiments, purified CD8 cells from wild-type or
CD103-deficient mice were adoptively transferred into
CD103 /  hosts with long surviving A/J allografts. To cir-
cumvent the likely requirement for an anti-donor CD4
(Th) response, the CD8 population was primed to A/J al-
loantigens 4 d before CD8 purification and transfer.
As shown in Fig. 3, transfer of highly-enriched CD8
cells into CD103 /  hosts elicited prompt rejection of
long-surviving A/J allografts. In contrast, transfer of the
same number of CD8 cells from CD103 /  donors com-
pletely failed to elicit rejection (Fig. 3). Moreover, treat-
ment of the wild-type CD8 preparation with anti-CD8
Figure 1. Survival of pancreatic islet allografts transplanted into
CD103 /  or CD103 /  hosts. Recipient mice were rendered diabetic
by treatment with streptozotocin, then transplanted with 500 islets under
the renal subcapsule; each line shown in A–C represents an individual re-
cipient mouse. (A) Survival of A/J allografts (black circles, n   13) or
BALB/c isografts (white circles, n     2) transplanted into CD103 / 
hosts. (B) Survival of A/J allografts (black circles, n   17) or isografts
(white circles, n   2) transplanted into CD103 /  hosts. (C) Unilateral
nephrectomy to remove the allograft (denoted by arrows) in CD103 / 
recipients with long surviving allografts results in a prompt return to hy-
perglycemic state (n   3).
Figure 2. Phenotypic characterization of CD8  T cells isolated from
rejecting islet allografts. Wild-type recipients were transplanted with A/J
islets as described in the legend to Fig. 1. At the time of rejection, lym-
phocytes were isolated from the graft and draining lymph node and sub-
jected to two-color FACS® analyses. (A) Dot plot of CD103 versus CD8
expression by GILs. (B) Expression of CD44, CD11a, CD62L, and
TCR-   by gated CD8  GILs; isotype controls are shown by the dashed
lines. Data are representative of four independent experiments.881 Feng et al.
mAb plus complement (non-CD8 cells in Fig. 3) com-
pletely abrogated its capacity to transfer rejection (Fig. 3).
Thus, these data demonstrate that CD8 cells in CD103 / 
hosts are deficient in their capacity to mediate rejection of
islet allografts.
CD103-deficient CD8 Cells Exhibit Normal Effector Re-
sponses to A/J Alloantigens and Efficiently Traffic to the Graft
Site. Despite their inability to mediate rejection of A/J is-
let allografts, CD8 cells in CD103 /  mice exhibited nor-
mal responsiveness to A/J alloantigens in conventional as-
says of CD8 activation and effector function. Fig. 4 shows
that CD8 effectors derived from CD103 /  and wild-type
mice mount comparable responses to A/J alloantigens both
with respect to IFN-  production (Fig. 4 A) and lytic ac-
tivity toward lymphoblast targets (Fig. 4 B). CD103 /  and
wild-type mice also exhibit comparable, albeit weak, pro-
liferative responses to A/J alloantigens (unpublished data).
An adoptive transfer model was devised to assess the effi-
ciency with which CD103-deficient CD8 effectors traffic
to the graft site. In this model, equal numbers (5   106) of
purified CD8 cells from CD103 /  (Thy1.1 /1.2 ) and
CD103 /  (Thy1.1 /1.2 ) donors were transferred into
syngeneic wild-type (Thy1.1 /Thy1.2 ) hosts which sub-
sequently received A/J islet allografts. Three-color FACS®
of GILs harvested at the time of early rejection (BG   200
mg/dL) were then used to quantitate relative numbers of
transferred CD8 populations which successfully trafficked
to the graft site. As shown in Fig. 5, CD103-deficient CD8
cells trafficked to the graft with efficiency comparable to
that of wild-type CD8 cells. In three independent experi-
ments, 18.7   1.4% (mean   SE) of the transferred cell
population was of CD103 /  origin as compared with 20.6  
5.8% of CD103 /  origin. Importantly, CD8 cells isolated
from such grafts were devoid of naive (CD62LhiCD44lo)
CD8 cells (unpublished data), thereby excluding the trivial
possibility that the graft-associated CD8 cells derived from
contaminating peripheral blood. Thus, these data demon-
strate that CD103 expression is not required for effective
Figure 3. Adoptive transfer experiments. 50   106 CD8  T cells from
CD103 /  (black squares) or CD103 /  donors (white circles) were
adoptively transferred into CD103 /  hosts with long surviving ( 50 d)
A/J islet allografts. The top and bottom panels show the results of two
independent experiments. Donors were immunized with 107 A/J SCs
intraperitoneally 4 d before cell isolation. A control group of CD103 / 
hosts with long surviving A/J islet allografts received 25   106 purified
non-CD8 cells from CD103 /  donors (black circles). Each line repre-
sents blood glucose levels from a single recipient mouse. CD8 cells for
these experiments were purified from combined spleens and lymph
nodes of primed donors by immunomagnetic depletion with mAbs to
CD4 and MHC class II, and comprised  60% CD8  T cells with
 0.1% CD4  T cells. The non-CD8 preparation was obtained by treat-
ment of the wild-type CD8 preparation with anti-CD8 mAb plus com-
plement and comprised  97% non-T cells (splenic B cells) with  0.01%
residual CD8  cells.
Figure 4. CD8 cells from CD103 /  mice exhibit normal responsive-
ness to A/J alloantigens in conventional assays of CD8 effector function.
CD8 effectors were generated by coincubation of SCs from CD103 /  or
CD103 /  mice with A/J SCs in 5-d mixed lymphocyte cultures, and
purified by negative selection with mAb plus complement. (A) IFN- 
production by CD8 effectors derived from CD103 /  (black circles) or
CD103 /  (white circles) in response to A/J SCs or media only (trian-
gles). Data shown are means ( SE) of three replicate values. (B) Lytic ac-
tivity of CD8 effectors derived from CD103 /  (circles) or CD103 / 
(triangles) to A/J (black symbols) and BALB/c (white symbols) lympho-
blast targets in standard 4-h 51[Cr] release assays. Data shown are means of
four replicate values; SD was  10% of mean values.882 CD103-dependence of Pancreatic Islet Allograft Rejection
activation of CD8 cells or trafficking of the resulting CD8
effectors to the general graft site.
Analyses of CD8 Cells that Infiltrate Islet Allografts in
CD103-deficient Hosts. Histological analyses of islet al-
lografts removed from wild-type hosts at the time of rejec-
tion showed that the islet grafts were infiltrated with large
numbers of lymphocytes of T cell morphology concomi-
tant with loss of graft function (Fig. 6 A). In marked con-
trast, long surviving allografts removed from CD103 / 
hosts (Fig. 6 B) were conspicuously free of infiltrating lym-
phocytes despite the presence of large numbers of lympho-
cytes in the subcapsular region. Similarly, islet allografts
transplanted into CD103 /  hosts and removed at the time
of rejection in wild-type hosts (day 14 after transplant)
showed pristine islet allografts despite massive accumulation
of lymphocytes in the subcapsular space (Fig. 6 C).
FACS® analysis revealed that lymphocytes infiltrating the
graft site in CD103 /  hosts (isolated at day 14 after trans-
plant) were predominantly TCR-    cells ( 70%) of
which  22% were CD8 cells (Fig. 7 A). Fig. 7 B shows that
CD8 cells in such grafts exhibited an activated/memory
phenotype. As shown in Fig. 7 C, the majority ( 96%) of
CD8 cells infiltrating such grafts were capable of rapid bursts
of IFN-  production after PMA/ionomycin stimulation,
thereby confirming their effector status. Taken together
with the above histologic analyses (Fig. 6, B and C), these
data strongly suggest that deficient allograft rejection in
CD103 /  hosts reflects a defect at the level of intragraft mi-
gration of CD8 effectors; i.e., CD103 is apparently required
for efficient entry of CD8 effectors into islet allografts.
Normal Rejection of Skin Allografts in CD103 /  Hosts.
In contrast to their impaired capacity to reject A/J islet al-
lografts, CD103 /  hosts were not deficient in the capacity
Figure 5. CD8 cells in CD103-deficient hosts traffic normally to the
graft site. Equal numbers (5   106) of purified CD8 cells from CD103 / 
(Thy1.1 /1.2 ) and CD103 /  (Thy1.1 /1.2 ) donors were transferred
into wild-type (Thy1.1 /Thy1.2 ) hosts which were subsequently trans-
planted with A/J islet allografts. At the time of rejection, GILs were stained
for three-color FACS® analyses with anti-Thy1.1-PE and anti-Thy1.2-
FITC in combination with anti-CD8a-CyChrome. Data shown are for
electronically gated CD8  lymphocytes. The quadrant on right shows the
relative positions of wild-type and CD103 /  cells in the density plot on
left. Data shown are representative of three independent experiments.
Figure 6. Graft histology. (A) Islet
allograft transplanted into wild-type
host harvested at the time of rejec-
tion (BG   300 mg/dL). (B) Long
surviving ( 100 d) islet allograft re-
moved from CD103 /  host as
shown in Fig 1 C. (C) Islet allograft
transplanted into CD103 /  host
and harvested at the time of rejection
in wild-type hosts (day 14 after trans-
plant). (D) Skin allograft transplanted
into wild-type host harvested at the
time of rejection (day 8 after trans-
plant). Arrows in A–C mark the po-
sition of islet allografts under the re-
nal subcapsule; the arrow in D marks
the postion of the graft epidermis.
Data shown are H&E staining of
paraffin-embedded sections.883 Feng et al.
to reject A/J skin allografts. CD103 /  and CD103 / 
hosts both rejected A/J skin allografts with similar kinetics:
mean   SEM   7.67   0.37 d (n   10) for wild-type ver-
sus 8.22   0.43 d (mean   SEM) (n   9) for CD103 / 
hosts (P   0.36). These data demonstrate that CD103 / 
mice do not possess a global defect in allograft rejection.
Given that skin allografts contain important epithelial el-
ements (epidermis), the lack of a requirement for CD103 in
rejection of skin allografts was unexpected. To explore this
issue more fully, histological analyses of A/J skin grafts
transplanted onto CD103 /  (Fig. 6 D) and CD103 /  re-
cipients (unpublished data) were performed. Rejection of
skin allografts in wild-type hosts is accompanied by massive
infiltration of lymphocytes into the dermis and vascular bed
of rejecting skin allografts yet the graft epidermis remains
strikingly free of lymphocytic infiltration (see arrow, Fig. 6
D). Note that the epidermis in rejecting allografts remains
intact except in focal areas with ischemic necrosis due to
the vascular damage and secondary infiltration by neutro-
phils. Parallel analyses of skin allografts in CD103-deficient
hosts revealed an identical histologic picture (unpublished
data). Thus, in contrast to islet allograft rejection, skin al-
lograft rejection in this strain combination apparently does
not occur via direct destruction of epithelial compartments
(epidermis) and, consequently, does not require CD103.
Discussion
The salient finding of this study is that expression of
CD103 is required for efficient destruction of graft epithe-
lial compartments by CD8 cells. This finding provides in-
sight into the important clinical problem of organ allograft
rejection. Similar to pancreatic islet allografts, the func-
tional elements of most commonly transplanted organs ex-
press E-cadherin and are vulnerable to CD8-mediated re-
jection (1, 2). Robertson et al. (15) recently demonstrated
that CD103  T cells selectively accumulate within the graft
tubular epithelium during clinical renal allograft rejection,
and we have shown that such cells possess a classic CD8 ef-
fector phenotype (CD8   TCR-   CD11ahiperforin ;
reference 27). This study provides compelling evidence
that a causal relationship exists between the CD103 CD8 
effector subset and destruction of graft epithelial elements,
and thus identifies CD103 as a novel target for therapeutic
intervention in organ allograft rejection.
The critical role of CD8 cells in rejection of pancreatic
islet allografts is well documented. CD8-deficient mice
show delayed rejection of islet allografts (28), and treatment
of wild-type mice with anti-CD8 mAb (29) or transplanta-
tion of MHC class I–deficient islets (30) leads to indefinite
survival of islet allografts. This study extends these findings
by demonstrating that CD103 expression by CD8 cells is
required for efficient islet allograft destruction. Initially, we
observed that CD8 effectors expressing high levels of
CD103 are present at the site of islet allograft rejection
(Fig. 2). Consistent with a role for such cells in the rejec-
tion process, islet allografts enjoyed strikingly prolonged
survival in CD103 /  hosts compared with CD103 / 
hosts (Fig. 1). That the defect in CD103 /  mice resides at
the level of the CD8 cell was established using adoptive
transfer experiments. CD8 cells from wild-type mice
promptly elicited rejection of long surviving allografts,
whereas CD8 cells from CD103 /  mice were completely
ineffectual in this regard (Fig. 3).
It remains to be determined how CD103 promotes de-
struction of islet allografts by CD8 cells. It is unlikely that
the deficiency in CD103 /  mice reflects suboptimal acti-
vation or maturation of host CD8 cells because CD103-
deficient CD8 effectors exhibit normal responsiveness to
A/J (leukocyte) targets in conventional assays of CD8 acti-
vation and effector function (Fig. 4). Consistent with these
in vitro observations, islet allografts in CD103 /  hosts are
Figure 7. Phenotypic analysis of lymphocytes that infiltrate pancreatic
islet allografts in CD103 /  hosts. CD103 /  recipients were transplanted
with A/J islets as described in the legend to Fig. 1. At day 14 after trans-
plant, GILs were isolated and subjected to FACS® analyses. (A) Dot plot
of TCR-   versus CD8 expression by GILs. (B) Expression of CD62L
(thin solid line), CD44 (thick solid line), and CD11a (dashed line) by
electronically-gated CD8  GILs. (C) IFN-  production by gated CD8 
GILs after PMA/ionomycin activation; identical results were obtained for
TNF-  production. Isotype control staining is shown by the gray peaks
in B and C.884 CD103-dependence of Pancreatic Islet Allograft Rejection
infiltrated with CD8 cells exhibiting the classic phenotypic
and functional properties of CD8 effectors (Fig. 7). Adop-
tive transfer experiments confirmed that CD103 expression
is not required for efficient trafficking of CD8 effectors to
the graft site (Fig. 5). The latter data are consistent with the
findings of Lefrancois et al. (19) who reported normal traf-
ficking of CD103-deficient CD8 cells from peripheral lym-
phoid tissues to the lamina propria and IEL compartments.
Thus, by process of elimination, these data strongly suggest
that the inability of CD103-deficient CD8 cells to reject is-
let allografts reflects a defect at the level of intragraft migra-
tion or delivery of effector function.
Given that islet allografts express the CD103 ligand,
E-cadherin, we favor the possibility that CD103 somehow
targets donor-reactive CD8 effectors to graft epithelial
cells, and thereby facilitates rejection. Importantly, com-
bined histological and FACS® analyses of islet allografts in
CD103 /  hosts (Figs. 6 and 7) revealed that CD8 effec-
tors successfully extravasate into the general graft site (the
renal subcapsule) but fail to accumulate within the islet al-
lograft itself. These data suggest that CD103 critically
functions to promote entry and/or retention of CD8 ef-
fectors into epithelial compartments. There is evidence
that cytokine production (31), particularly IFN-  (5), and
not the perforin or Fas/FasL pathways (5, 32) is critical for
islet allograft destruction by CD8 cells. Recent studies in
cardiac (33, 34), skin (35), and tumor (36) rejection mod-
els indicate that IFN-  produced by graft infiltrating CD8
effectors impacts graft survival by inducing intragraft ex-
pression of the CXC chemokines, IP-10 and Mig, which
are potent chemoattractants for activated T cells. Based on
these data, we postulate that the salient role of CD8 
CD103  effectors in islet allograft rejection, by virtue of
their unique capacity to interact with epithelial layers, may
be to guide the migration of other inflammatory cells into
critical areas of the graft (i.e., the graft functional ele-
ments). Consistent with this hypothesis, although islet al-
lografts in wild-type hosts are thoroughly penetrated with
infiltrating lymphocytes (Fig. 6 A), CD8 CD103  cells com-
prise only a small fraction ( 10%) of such cells (Fig. 2 A).
Indeed, CD103  CD8  ( 35%) and CD103 CD8  cells
( 50%, likely CD4 cells and B cells) comprise the vast
majority of GILs (Fig. 2 A). These data suggest that
CD103 CD8  cells and other inflammatory cells are
helped into the graft by a small subset of CD103 CD8 
cells which effectively penetrate the graft. Studies using
chemokine/cytokine-deficient donors and hosts are un-
derway to definitively test this hypothesis.
Studies of IEL populations provide precedent that
CD103 can target T cells to epithelial layers. Consistent
with a role for CD103 in promoting retention of T cells in
the mucosal epithelium, the distribution of CD103  IEL
within the gut epithelium correlates with expression of
E-cadherin, and CD103-deficient mice exhibit a specific
deficiency (albeit mild) of TCR-    cells in the IEL com-
partment (18). Furthermore, CD103 has been shown to
promote adhesion of intestinal IEL to epithelial cell lines in
vitro (11, 12, 37), and there is evidence that CD103/E-
cadherin adhesive interactions are enhanced by signaling
through the TCR complex (37).
This data does not exclude a role for CD103 in promot-
ing cytolysis of islet allografts and/or intragraft expansion of
CD8 effectors subsequent to their migration into epithelial
compartments. There is evidence that CD103-mediated
signaling promotes both proliferation (38, 39) and cytolytic
activity (21, 40) of IEL populations, and we have previously
shown that anti-CD103 mAbs inhibit lysis of epithelial tar-
gets by allospecific (CD103 ) CTL clones (14). The current
dogma is that LFA-1 (CD11a/b1) plays a dominant role in
delivery of CD8 effector function through recognition of
its broadly expressed ligand, intracellular adhesion molecule
(ICAM)-1 (41). CD103 CD8  cells that infiltrate islet al-
lografts express high levels of LFA-1 (CD11a, Fig. 2 B), but
it remains unclear whether islet allografts express significant
levels of ICAM-1. Although mouse islets can be induced to
express ICAM-1 in vitro with inflammatory cytokines (42),
in vivo studies indicate that ICAM-1 expression within in-
flamed islets is limited to infiltrating leukocyte populations
(43); furthermore, treatment of islet allografts with ICAM-1
antisense oligodeoxynucleotide is ineffective in prolonging
graft survival (44). Conversely, islets and other epithelial
structures constitutively express the CD103 ligand, E-cad-
herin (20). Thus, CD103/E-cadherin interactions have the
potential to impact CD8 effector function at multiple levels
including not only migration into epithelial compartments
but also in subsequent destruction of epithelial targets.
The concept that CD103 may promote migration of
CD8 effectors into epithelial compartments is at odds with
the findings of Lefrancois et al. (19), who used adoptive
transfer of TCR-transgenic CD8 cells on a CD103 / 
background to demonstrate that CD103 is not required for
retention of CD8 cells within the intestinal IEL compart-
ment. However, it is important to note that the Lefrancois
study examined migration of OVA-specific CD8 cells into
the gut following systemic immunization with OVA con-
structs; thus, it is not clear that OVA was expressed within
the IEL compartment examined. Conversely, the CD8 re-
sponse examined in the present study (BALB/c anti-A/J) is
likely directed to the mismatched class I alloantigen (H-
2Kk) which is well expressed by the epithelial compartment
(islet allograft) in question. As discussed above, CD103/E-
cadherin adhesive interactions are regulated by signaling
through the TCR complex (37). Thus, the dramatic im-
pact of CD103 on CD8 effector responses noted in the
present study may depend on corecognition of MHC/pep-
tide in the context of epithelial layers.
The present finding that CD103 /  hosts exhibit normal
rejection of skin allografts was unexpected given that the
skin contains important epithelial structures (keratinocytes
comprising the epidermis). However, histologic analyses
revealed that skin allograft rejection in the A/J to BALB/c
strain combination does not involve direct T cell–mediated
destruction of epithelial structures (epidermis) but rather
reflects destruction of the underlying support structures
leading to necrosis of the overlying epidermis (Fig. 6 D).
These data are consistent with the findings of Wolman et885 Feng et al.
al. (45) who reported that skin allograft rejection in BALB/c
hosts reflects occlusion of blood vessels at the graft-host
border with ischemia of the graft. Unlike islet allografts,
skin allografts are highly vulnerable to CD4-mediated re-
jection (1, 2); moreover, A/J donors are fully mismatched
from BALB/c at MHC class II alleles (I-Ak and I-Ek).
Thus, destruction of skin allografts in this strain combina-
tion is likely mediated by CD4 effectors directed to class II
alloantigens expressed by the graft vasculature, whereas islet
rejection is likely mediated by CD8 effectors directed to
class I alloantigens expressed by the graft functional ele-
ments (insulin-producing   cells). It is important to note,
however, that this data does not exclude a role for CD103
in promoting CD8-mediated destruction of skin allografts
in other strain combinations or transplant scenarios.
These findings are consistent with a general role for
CD103 in facilitating immune surveillance of epithelial
compartments by CD8 cells. The CD103 ligand, E-cad-
herin, functions at the level of adherent junctions (13) to
promote homotypic interactions between adjacent epithe-
lial cells and, consequently, is selectively yet ubiquitously
expressed by cells comprising epithelial layers. Importantly,
the initial site of attack by intracellular parasites is generally
an epithelial layer (i.e., the mucosa of the skin, lungs, and
gut), and there is abundant evidence that CD8-mediated
destruction/neutralization of the infected epithelial cells is
often required for clearance of such pathogens (46). Indeed,
CD103 CD8   TCR-    cells with potent cytolytic
capability (albeit of unknown specificity) are abundantly
present within the IEL and LPL compartments of normal
individuals (47), where they are thought to function as an
initial line of defense against frequent microbial attack at
such sites. A role for CD103 CD8  effectors in surveil-
lance against tumors of epithelial origin (48), and as an ef-
fector mechanism in the epithelial lesions characteristic of
GVHD (49) and autoimmune pathology (50) is also plausi-
ble. It will now be important to determine the extent to
which these diverse sites are permissive for the induction/
maintenance of CD103 expression by antigen-specific CD8
effectors, as this likely represents the salient factor limiting
the role of CD103 in CD8-mediated immune responses.
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